WO2014029360A1 - 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 - Google Patents
氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 Download PDFInfo
- Publication number
- WO2014029360A1 WO2014029360A1 PCT/CN2013/082166 CN2013082166W WO2014029360A1 WO 2014029360 A1 WO2014029360 A1 WO 2014029360A1 CN 2013082166 W CN2013082166 W CN 2013082166W WO 2014029360 A1 WO2014029360 A1 WO 2014029360A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- substituted
- amino
- preparation
- obesity
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims abstract description 29
- -1 Amino-substituted rutaecarpin analog Chemical class 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 6
- 238000001308 synthesis method Methods 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- ACVGWSKVRYFWRP-UHFFFAOYSA-N Rutaecarpine Natural products C1=CC=C2C(=O)N(CCC=3C4=CC=CC=C4NC=33)C3=NC2=C1 ACVGWSKVRYFWRP-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000883 anti-obesity agent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- BCPAKGGXGLGKIO-UHFFFAOYSA-N Pseudorutaecarpin Natural products C1=CC=C2C(=O)N(CCC3=C4C5=CC=CC=C5N3)C4=NC2=C1 BCPAKGGXGLGKIO-UHFFFAOYSA-N 0.000 claims description 5
- 238000005660 chlorination reaction Methods 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 4
- FGWYWKIOMUZSQF-UHFFFAOYSA-N 1,1,1-triethoxypropane Chemical compound CCOC(CC)(OCC)OCC FGWYWKIOMUZSQF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims 3
- 239000012752 auxiliary agent Substances 0.000 claims 1
- MHCWIVKXRYEVDS-UHFFFAOYSA-N benzene hydrazine Chemical compound NN.C1=CC=CC=C1.C1=CC=CC=C1 MHCWIVKXRYEVDS-UHFFFAOYSA-N 0.000 claims 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical group NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims 1
- 229940067157 phenylhydrazine Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 14
- 235000020824 obesity Nutrition 0.000 abstract description 14
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 8
- 210000001789 adipocyte Anatomy 0.000 abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229960002737 fructose Drugs 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 20
- 238000009825 accumulation Methods 0.000 description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 18
- 239000002609 medium Substances 0.000 description 14
- 239000005715 Fructose Substances 0.000 description 10
- 229930091371 Fructose Natural products 0.000 description 9
- 229910052707 ruthenium Inorganic materials 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- TXDUTHBFYKGSAH-SFHVURJKSA-N Evodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC=CC=4)=C5CCN3C(=O)C2=C1 TXDUTHBFYKGSAH-SFHVURJKSA-N 0.000 description 4
- HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000019624 protein content Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 1
- XHZFHAGIQPYPAM-UHFFFAOYSA-N 3-hydroxy-1-[(4-methoxyphenyl)methyl]piperidin-2-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(O)CCC1 XHZFHAGIQPYPAM-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- ZADCUMFVTUWSAW-UHFFFAOYSA-N CCCC1(CC1)N Chemical compound CCCC1(CC1)N ZADCUMFVTUWSAW-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960005259 diethylpropion hydrochloride Drugs 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QOHMWDJIBGVPIF-UHFFFAOYSA-N n',n'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960001277 phentermine hydrochloride Drugs 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Definitions
- the present invention relates to the field of medicinal chemistry and pharmacotherapy, and in particular to the use of amino substituted ruthenium base analogs and methods for their synthesis and in the preparation of anti-obesity drugs. Background technique
- Body mass index (BMI is the weight divided by the square of height: ⁇ 30kg / m 2 is obesity.
- BMI Body mass index
- Obesity is an important cause of type 2 diabetes and cardiovascular disease. Therefore, obesity and its complications It has become a worldwide public health problem that poses a serious threat to human health and quality of life.
- Wusong is a traditional Chinese medicine. It is a near-mature fruit of the genus Rutaceae. It is contained in Shennong Materia Medica and is mainly used for the treatment of gastrointestinal diseases, hypertension, angina pectoris and rheumatoid arthritis. Wusong contains a variety of alkaloids, limonin, and volatile oils. Evodiamine (mtaecarpine, Rut,
- Indole base has a wide range of pharmacological effects against gastric mucosal damage, anti-inflammatory and analgesic, blood pressure lowering, and relaxing blood vessels.
- rutaecarpine can reduce cell fat accumulation.
- the compound has poor water solubility and solubility in water of only 0.05 ⁇ 0.02 g/m, resulting in poor oral absorption and low bioavailability, which will limit its application prospects in the treatment of obesity. Summary of the invention
- An object of the present invention is to provide an amino-substituted sulphonic acid analog and a synthetic method thereof, and the use of the compound in the preparation of an anti-obesity drug.
- the inventors carried out structural modification and optimization studies on the basis of the ruthenium base structure, and found ruthenium base analogues with better activity and higher bioavailability.
- the ruthenium base analog (Formula 1) according to the present invention is characterized in that the six-membered ring structure of the C ring in the structure of the ruthenium base is changed to a five-membered ring, and then a different amino side chain is introduced at the 8-position. .
- Pharmacological tests have shown that the compound of formula I has a stronger ability to accumulate fat than rutaecarpine and is more medicinal.
- R 2 -N(CH 3 ) 2 -N(CH 2 CH 3 ) 2 pentylamino or cyclohexylamine; or, Orolinyl, piperazinyl or methylpiperazinyl.
- the present invention also provides a process for the preparation of the above amino-substituted sulphonic acid analog.
- the synthesis process is as follows: The specific preparation method steps are: reaction of anthranilamide 1 with triethyl orthopropionate
- Target product 7 v H (compound of formula 1).
- R 0 morpholinyl, piperazinyl or methylpiperazinyl.
- compound 4 is prepared When the molar ratio of compound 3 to benzoquinone is 1: 2-6
- the compound 5 is reacted with phosphorus oxychloride at room temperature, and the compound is obtained by cyclization and chlorination.
- the target product of the above preparation method is purified by column chromatography.
- the invention also provides the use of the above amino-substituted ruthenium base analog in the preparation of a medicament for preventing fat, phlegm and fat. It can also be used to prepare anti-fatty liver and drugs for diabetes and cardiovascular diseases induced by obesity.
- the amino-substituted ruthenium base analog (Formula 1) of the present invention not only reduces the fat accumulation of fat cells in 3T3-L1 mice, but also reduces the fat accumulation of liver cells induced by high fructose in FAO rats. This suggests that rutaecarpine analogues may not only reduce fat accumulation by inhibiting lipogenesis, but also reduce fat accumulation by promoting the oxidation of fatty acids.
- the invention also provides an anti-obesity drug, which has the effects of reducing fat accumulation, reducing obesity, relieving fatty liver and the like.
- Such compounds are useful in the treatment of obesity and related diseases such as diabetes and cardiovascular diseases caused by obesity.
- Such drugs contain the above-described amino-substituted sulphonic acid analogs and pharmaceutically acceptable adjuvants.
- the medicament can be used in the form of an injection, a tablet, a pill, a capsule, a suspension or an emulsion.
- the route of administration can be oral, transdermal, intravenous or intramuscular. riJ ij Vli "J 4
- Figure 1 Example 10 Effect of rutaecarpine R1 and compound I on fat accumulation in 3T3-L1 cells (compound concentration 1 ⁇ ⁇ ).
- Example 10 evodiamine R1 and the compound of formula I reduce the fat accumulation of 3T3-L1 cells in a concentration-dependent manner; the compound concentration R1 is 0, 0.3, 1, 3, 10, 15 ⁇ M; R17 and R18 are 0, 0.03, 0.1, 0.3, 1, 3 ⁇ ⁇ ; for ease of mapping, set 0 ⁇ ⁇ to 0.0001 ⁇ ⁇ .
- FIG. 3 Example 10, Day 6 of Cell Differentiation (Day6) Microscope The morphology of cells in the control group BM, DMSO blank control group DM, and different drug groups in the field of 4x mirror.
- FIG. 4 Example 10, 15 M Rl, R17 and R18 were incubated with the cells for 6 days (changed every three days), and photographed on the sixth day (Day 6) with a microscope; the needles in the figure were from the medium. The R1 solid precipitated out.
- Example 11 evodiamine R1 and compound of formula I (R17) reduced the fat accumulation of hepatocytes induced by high fructose in HE rats in a concentration-dependent manner; compound concentration R1 was 0, 0.3, 10, 20 ⁇ M; 0, 0.1, 0.3, ⁇ ⁇ ⁇ ; For ease of drawing, set 0 ⁇ ⁇ to 0.0001 ⁇ ⁇ .
- Figure 6 A photograph of a compound R1, R17, and R18 incubated with cells for 24 hours and photographed with a microscope. The needles in the figure are R1 solids precipitated from the medium. detailed description
- Example 10 The 3T3-L1 mouse adipocyte model was used to evaluate the effect of rutaecarpine R1 and the compound of formula I (R17, R18) on reducing cell fat accumulation by microscopic photographing and triglyceride content assay kit analysis. .
- the experiment set the basic control group BM, DMSO blank control group DM, and different drug groups R1 (Wulthenoline) group, R17 group, R18 group.
- the specific operations are as follows:
- 3T3-L1 preadipocytes were seeded in 48-well plates. First culture in basal medium until the cells are ligated After the componentization, the medium was incubated for another 3 days (Day 6). When the drug group was in DayO and Day3, the corresponding drug was diluted in fresh medium and added together. The basal control group and the DMSO blank control group were added with the corresponding amount of DMSO. At Day 6, a microscope (4x objective) was used for photographing and the kit was used for triglyceride content analysis.
- Drug solution Dissolved in dimethyl sulfoxide (DMSO, dimethylsulfoxide), formulated into 10 mM concentration, stored at -20 ° C in a low temperature refrigerator, diluted with the corresponding culture solution to the desired concentration when used, so that the final concentration of DMSO is less than or equal to 0.1% ( v / v
- Basic medium DMEM high sugar medium +10% newborn bovine serum
- Differentiation medium Add triple inducer to basal medium 0.5 mM isobutyl-methyl-xanthine, lng/ml dexamethasone, 2 ⁇ g/mL insulin
- the above cells were discarded, washed twice with PBS, and added with 50 mM potassium hydroxide solution at 60 ° C for 10 min to fully lyse the cells, homogenize the cell suspension, and determine the glycerol according to the instructions of the triglyceride assay kit. The content of the ester.
- the final result of the triglyceride content analysis is expressed as "100% control" (i.e. (triglyceride content of the drug group / triglyceride content of the control group) * 100%).
- the drug concentration of the DMSO blank control group was set to 0.0001 ⁇ ⁇ .
- the experimental results are the average of three independent experiments.
- the triglyceride content of the drug group was lower than that of the DMSO blank control group, and there was a statistically significant difference between the two groups, indicating that the compound can reduce the fat accumulation of 3T3-L1 adipocytes.
- DM is a DMSO blank control group, which represents normal differentiated cells, and has a large amount of fat accumulation; R1 is evodiamine, and R15-R18 is an amino-substituted ruthenium base analog.
- the positive control was 3 ⁇ berberine (BBR).
- 1 ⁇ M of compounds R1, R15, R17, and R18 can significantly reduce the triglyceride content of cells (*, P ⁇ 0.5 ; **, / o I , z ⁇ /y ⁇ /JH /J/J t ⁇ / ⁇ ⁇ J > ⁇ I J3 ⁇ 4> V jyji - ⁇ o
- Figure 2 shows that ruthenium base R1 and compound of formula I (R17 R18) can The fat accumulation of 3T3-L1 cells was decreased in a concentration-dependent manner (*, P ⁇ 0.5;**P ⁇ 0.1;***P ⁇ 0.001), while R17 and R18 were more active.
- the content of triglyceride in cells treated with 3 M R17 and R18 was reduced by 93% and 72%, respectively.
- the triglyceride content was only reduced by 34%.
- BM is the basic control group, representing undifferentiated cells, with no fat accumulation. It can be visually found from the pictures that there is almost no accumulation of lipid droplets in the BM of the basic control group, while dense lipid droplets can be clearly seen in the DMSO blank control group, while the lipid droplets in the drug group gradually decrease with the increase of the drug concentration. .
- Example 11 Another cell strain, FAO rat hepatocytes, was used as a model, and the ruthenium base R1 and the compound of formula I (R17) were evaluated in vitro using a triglyceride content determination kit and a BCA protein concentration assay kit. Fructose-induced hepatocyte fat accumulation reduces the effect.
- the experiment set the baseline control group Bas (without fructose), the DMSO blank control group Fm (containing high fructose), and the different drug groups R1 and R17.
- the specific operations are as follows:
- the rat rat hepatocytes were inoculated into a 24-well plate at 5*10 5 cells/well, cultured for 24 hours, and then exchanged for the sugar medium, and then cultured for 24 hours, and then the triglyceride and protein contents were measured, and the results were analyzed.
- the drug group was diluted with the fructose medium to the desired concentration, and added together for 24 hours.
- the basal control group and the DMSO blank control group were added with the corresponding amount of DMSO, and the same amount of incubated for 24 hours.
- Fructose medium low sugar Add 25 mM fructose to DMEM medium, add 10% newborn bovine serum
- the above cells were discarded, washed twice with PBS, and added with 1 M potassium hydroxide solution at 60 ° C.
- the content of triglyceride per well is determined, and the protein content of each well is determined according to the instructions for use of the BCA protein content determination kit.
- triglyceride levels is expressed as nmol/mg protein.
- the result was converted to a "100% control" mode (ie, the triglyceride content of the drug group (nmol/mg protein) / the triglyceride content of the control group. (nmol/mg protein) *100%).
- the drug concentration of the DMSO blank control group was set to 0.0001 ⁇ ⁇ .
- the experimental results are the average of three independent experiments.
- Figure 5 shows that the indole base R1 and the compound of the formula I (R17) inhibited high fructose-induced fat accumulation in the liver of FAO rats in a concentration-dependent manner. It can be clearly seen that at a concentration of ⁇ ⁇ , the high-fructose-induced fat accumulation in the R1 group was reduced by 72%, while the R17 group was reduced by 92% (*, ⁇ 0.5 ; **, ⁇ 0.1; ** *, ⁇ 0.001
- Figure 6 is a photograph of a compound Rl, R17, and R18 photographed with a microscope after incubation with cells for 24 hours. It can be clearly seen from the figure that R1 will precipitate out of the medium at 20 ⁇ due to poor water solubility, whereas this phenomenon does not occur with 20 ⁇ of R17 and R18.
- the needle circled in the box in the figure is the solid which is precipitated from the medium. Again, the water solubility of the analogs R17 and R18 is indeed better than R1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物化学和药物治疗学领域,提供了一种氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用。实验证明,本发明提供的氨基取代吴茱萸次碱类似物能够显著减少3T3-L1脂肪细胞的脂肪蓄积,并能减少高果糖诱导的FAO大鼠肝细胞的脂肪蓄积。细胞水平的试验表明该类化合物能减少脂肪积累,具有减轻肥胖症状和缓解脂肪肝的作用。所述氨基取代吴茱萸次碱类似物的化学式如式(I)所示,式中R0=-NH(CH2)nR2,n=1、2、3、4或5,R2=-N(CH3)2、-N(CH2CH3)2、环戊胺基或环己胺基;或者R0=吗啉基、哌嗪基或甲基哌嗪基。
Description
氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 技术领域
本发明涉及药物化学和药物治疗学领域, 具体涉及氨基取代吴茱萸次碱类 似物及其合成方法与在制备抗肥胖症药物中的应用。 背景技术
肥胖症, 是一种由于机体能量过剩和低活动量引起的长期能量摄入和能量 消耗不平衡导致的临床代谢性疾病。 世界卫生组织规定: 体重指数 (BMI即体重 除以身高的平方:^ 30kg/m2时即为肥胖。肥胖是导致 2型糖尿病和心血管疾病等 的重要原因。 因此, 肥胖症及其并发症已成为严重威胁人类健康和生活质量的 世界性公共卫生问题。
由于生活方式和饮食结构的改变, 近年来, 肥胖症患者逐年增多。 2005年 世界卫生组织评估结果显示, 全球成年超重和肥胖患者分别为 16亿和 4亿, 预计 到 2015年上述两项数据将分别上升到 23亿和 7亿。 在全球肥胖症快速发展的情况 下, 相关治疗药物的发展相对滞后, 目前在全球范围内正式获准临床应用的抗 肥胖药物仅有三个。 其中两个是去甲肾上腺素能药物盐酸芬特明 (phentermine hydrochloride)和盐酸安非拉酮 (diethylpropion hydrochloride), 另一个是脂酶抑 制剂奥利司他 (orlistat/Xenical, Alli)。可供选择的药物不仅数量少,且还存在疗效 有限、 长期服用的安全性问题和停药后体重易反弹等缺陷。 因此, 临床迫切需 要有新的更有效、 更安全的抗肥胖症药物。
肥胖症的发生与遗传和环境因素有关, 发病机制具有多样性和复杂性。 目 前的研究认为, 过度的脂肪生成和体内脂肪氧化能力的下降是导致肥胖的两个 重要原因。 因此在研究如何抑制脂肪生成或者提高脂肪酸氧化能力, 从而减少 脂肪蓄积的基础上, 寻找和开发出新的抗肥胖症药物, 是目前的研究热点之一。
吴茱萸是一种传统中药, 是芸香科植物吴茱萸将近成熟的果实, 始载于神 农本草经, 主要用于治疗胃肠道疾病、 高血压、 心绞痛、 风湿性关节炎等。 吴 茱萸中含有多种生物碱、 柠檬苦素、 挥发油等。 吴茱萸次碱 (mtaecarpine, Rut,
茱萸次碱具有抗胃黏膜损伤、 抗炎镇痛、 降血压、 松弛血管等广泛的药理作用。
发明人研究发现, 吴茱萸次碱能减少细胞的脂肪蓄积。 但该化合物水溶性 差, 在水中的溶解度仅有 0.05 ±0.02 g/m, 导致口服吸收差, 生物利用度低, 这将会限制它在肥胖症治疗上的应用前景。 发明内容
本发明的目的是提供一种氨基取代吴茱萸次碱类似物及其合成方法, 以及 该类化合物在制备抗肥胖症药物中的应用。
发明人在吴茱萸次碱结构基础上进行了结构修饰和优化研究, 发现了活性 更好、 生物利用度更高的吴茱萸次碱类似物。本发明所涉及的吴茱萸次碱类似 物 (式 1), 其结构特征是将吴茱萸次碱结构中 C环的六元环结构改为五元环, 然后再在 8位上引入不同的氨基侧链。 药理学试验证明, 式 I化合物减少脂肪 蓄积能力比吴茱萸次碱更强, 而且成药性更好。
为达到上述目的, 本发明提供的氨基取代吴茱萸次碱类似物的化学式如式
I所示 (以下简称为式 I化合物
式 I
式 I中,
Ro = -NH(CH2)„R2 n = l 2 3 4或 5 R2= -N(CH3)2 -N(CH2CH3)2 戊胺基或环己胺基; 或者, 吗啉基、 哌嗪基或甲基哌嗪基。
本发明还提供了上述氨基取代吴茱萸次碱类似物的制备方法。
合成过程如下:
具体的制备方法步骤为:邻氨基苯甲酰胺 1 与原丙酸三乙酯反应
(加热回流反应), 得到化合物 。 化合物 2经溴化后得到化合 ί
人
优选地, 上述制备方法中的取代胺化合物为 HRQ, Ro = -NH(CH2)nR2, n = 1、 2、 3、 4或 5, R2 = -N(CH3)2、 -N(CH2CH3)2、 环戊胺基或环己胺基; 或者
R0 = 吗啉基、 哌嗪基或甲基哌嗪基。
优选地, 化合物 5在室温下与三氯氧磷反应, 经环合氯代后得到化合物 、 、
6 Η 。 上述制备方法的目标产物通过柱层析进行纯化。
本发明还提供了上述氨基取代吴茱萸次碱类似物在制备抗肥, Ί,胖症药物中 的应用。同时还能够用于制备抗脂肪肝以及由肥胖诱发的糖尿病和心血管疾病 的药物。
通过细胞实验表明, 本发明的氨基取代吴茱萸次碱类似物 (式 1 ) 不仅能 减少 3T3-L1小鼠脂肪细胞的脂肪蓄积,还能减少高果糖诱导的 FAO大鼠肝细 胞的脂肪蓄积。这提示吴茱萸次碱类似物可能不仅能通过抑制脂肪生成来减少 脂肪蓄积, 还能通过促进脂肪酸的氧化的途径来减少脂肪积累。
本发明还提供了一种抗肥胖药物,该类药物具有减少脂肪积累、减轻肥胖、 缓解脂肪肝等功效。 该类化合物可用于治疗肥胖症以及肥胖引起的糖尿病、心 血管疾病等相关疾病。该类药物含有上述的氨基取代吴茱萸次碱类似物以及药 学上可接受的辅助剂。 该药物可以制成注射剂、 片剂、 丸剂、 胶囊剂、 悬浮剂 或乳剂的形式使用。 其给药途径可为口服, 经皮, 静脉或肌肉注射。
riJ ij Vli "J 4
图 1:实施例 10吴茱萸次碱 R1和式 I化合物对 3T3-L1细胞的脂肪蓄积的 影响 (化合物浓度 1 μ Μ)。
图 2: 实施例 10吴茱萸次碱 R1和式 I化合物 (R17、 R18)浓度依赖性地 减少 3T3-L1细胞的脂肪蓄积; 化合物浓度 R1为 0, 0.3, 1, 3, 10, 15 μ M; R17 和 R18为 0, 0.03, 0.1, 0.3, 1, 3 μ Μ; 为方便作图, 设 0 μ Μ为 0.0001 μ Μ。
图 3: 实施例 10, 细胞分化的第六天 (Day6) 显微镜 4倍镜的视野下,基 础对照组 BM, DMSO空白对照组 DM, 以及不同药物组的细胞的形态。
图 4: 实施例 10, 15 M Rl , R17和 R18与细胞孵育 6天 (每三天换一 次液), 在第六天 (Day6) 用显微镜拍照所得图片; 图中针状物为从培养基中 析出来的 R1固体。
图 5 : 实施例 11吴茱萸次碱 R1和式 I化合物 (R17 ) 浓度依赖性地减少 了高果糖诱导的 FAO大鼠肝细胞脂肪蓄积;化合物浓度 R1为 0, 0.3, 10, 20 μ M ; R17为 0, 0.1, 0.3, ΙΟ μ Μ; 为方便作图, 设 0 μ Μ为 0.0001 μ Μ。
图 6: 化合物 Rl、 R17、 R18与细胞孵育 24 h后用显微镜拍照所得图片, 图中针状物为从培养基中析出来的 R1固体。 具体实施方式
实施例 1: 化合物 2的合成
在 10 1111的原丙酸三乙酯中加入0.0111101邻氨基苯甲酰胺, 155°C加热回 流 12h后, 冷却至 0°C静置 l〜2h, 小心滤取结晶, 用少量的乙醇洗涤, 真空 干燥后得到白色针状结晶 2。
产率: 71% ; ¾-NMR (400 MHz, DMSO) δ (ppm): 12.12 (s, 1H), 8.08 (dd, J = 7.9, 1.4, 1H), 7.83 - 7.73 (m, 1H), 7.60 (d, J = 8.1, 1H), 7.51 - 7.41 (m, 1H), 2.62 (q, J = 7.5, 2H), 1.25 (t, J = 7.5, 3H); ESI-MS m/z: 175 [M+H]+.
OL'L '(HI 'ZH Γ8 = Γ 'P) VL'L '(HI 'ZH 9'L = Γ Ί) £S'L '(HI 'ZH L' L = Γ 'Ρ) 9Γ8 '(HI 's) 6 U '(HI 's) : (mdd) s (OSVO 'ZHW OOt) ¾VN-HT '·%69
ς w :p m^
[u+n\ 6LZ :z/ra SPV-ISH m 's) g z '(HI = r V 68·9 '(H^
'8'L = Γ V SZ'L '(HI 'L = Γ Ί) 81·Δ '(IK 'Γ8 = Γ 'Ρ) S£'L '(HI 'Γ8 = Γ 'Ρ) L9'L '(HI 9L'L― '(HI Tl = Γ 'ΡΡ) £Γ8 '(HI 's) 98·6 '(HI 's) 9ΡΊΙ 9 (OSMO 'ZHV 0017) ¾VN HI : (^dd) 9 (OSMO '^HM OOP) ¾VN-HT %Z8 士 ^黎^裁 晷 ¾ ' m ' M^ ^ m^^m ^
'qoi ^ W 'ΦΙΙ^ ^ im08 i°mi70 a ε W \o o-o琳
p w: ε m^
°ε W
ίη+η] £ςζ · ' SPV-ISH m '8·9 = r 'ρ) \οτ '(HI '8·9 = r 'b) ονς '(HI 'ς'ί = r 'ι) ςς'ί '(HI Τ8 = r 'ρ) 69' L '(HI 08·Δ - LS'L '(HI 60·8
- 9Γ8 '(HI 's) 9VZ\ :(radd) s (OSVO 'ZHPV 001) ¾VN-HT -%69
°ε ^囤 K録 士 簟 'wm ^M ^^ 'Φ«
'^ 0M M ™i ^ ¾a i°mio-o阜谬 ϋϊ敏 篛??一 ' ^¾一 ' ο„ 八 v Hr/ ί I "ΧΜ 1 r. Η ττττ八 τΛ.Λ-Ο ϋΛ tM "ΧΜ ι ~ > τηττττη-η C/λ. Μ nJ τηττττη-η 「、 I,
991Z80/C10ZN3/X3d 09£6Z0/ 0Z OAV
11"1, 一 . J , / 一
化合
实施例 5: 化合物 6的合成
在 N2保护的条件下,在 0°C时将 0.011molPOCl3滴加到 25mlDMF中形成 粘稠的黄色溶液, 然后滴加 O.Olmol化合物 5与 DMF的混合液, 0°C时大约滴 力口 0.5h, 然后室温搅拌反应 24h, 反应液倒入 300ml冰水中, 产生黄色固体, 抽滤干燥后得棕黄色固体, 粗品用氯仿柱层析, 得到黄色固体 6
产率: 30% ¾-NMR (400 MHz, DMSO) δ (ppm) Ή NMR (400 MHz, DMSO) δ 12.77 (s, IH), 11.22 (s, IH), 8.36 (d, J = 8.3, IH), 8.31 (d, J = 7.9, IH), 8.26 - 8.11 (m, 2H), 7.97 - 7.89 (m, IH), 7.68 (d, J = 8.2, IH), 7.36 (t, J = 7.6, IH), 7.28 (t, J = 7.5, IH), 1.23 (s, IH); 1[M+H]+.
化合物 6
实施例 6: 化合物 R15的合成
将 O.OOlmol化合物 6加入到 10 ml的甲苯中, 吸取 100 的三乙胺, 650 μΐ的 1-甲基哌嗪加入到反应液中, 加热回流 6h, 停止反应后冷却至室温, 蒸 除甲苯, 用氯仿 /甲醇 (15: 1 ) 柱层析纯化后得到棕黄色固体粉末 R15
产率: 60%; ¾-NMR (400 MHz, CDC13) δ (ppm): 11.41 (s, IH), 10.07 (s, IH), 8.53 (d, J = 7.6, IH), 7.91 (t, J = 8.5, 2H), 7.78 (d, J = 7.4, IH), 7.50 - 7.45 (m, 2H), 7.31 (dd, J = 16.6, 8.1, 2H), 3.88 (s, 4H), 2.68 (s, 4H), 2.40 (s, 3H) ; ESI-MS m/z: 371[M+H] +.
•+[H+W]1 ,
SPV-ISH HC 081 - Wl '(Η9 'S) 9£'Z UZ Z£'Z― £9'Z Xuz 'S'S ΊΌΙ = r pp) ςίτ Χης '6·9 'cm = r 'ρι) ZL HZ '8·9 = r 'ιρ) '(HI T8 = r ' )
'(HI '9·Δ = Γ Ί) 99' L '(HI 'ε·8 = Γ 'Ρ) 9L'L '(HI '£·8 = Γ 'P) 9VS '(HI 's) 80·6 '(HI 's) 17ΙΌΙ '(HI 's) ZVU :(冚 dd) s
'z丽 OOt)丽 ΝΉΤ
^ L ^ :8 m^
。9I ^
•+[H+ v]6ee :z/tusw-iS3 m
ZS'i― LS'i '(H17 ς '£― 66'ί UZ ί '0·8ΐ = Γ 'ΡΡ) ££'L UZ LVL ― '(HI '9·Δ = Γ Ί) 08·Δ ηΖ 'ε·8 '9·9ΐ = Γ 'ΡΡ) WL '(HI 'LL = Γ 'Ρ) £S'8 '(HI 's ) CO T '(HI 's) IVll :(冚 dd) s (£uaj 'z丽 001)霸 ΝΉΤ -%Z9
。£13 ^
化合物 R17。
实施例 9: 化合物 R18的合成
方法同实施例 6, 所不同的是用 3-二乙胺基丙胺代替 3-二甲胺基丙胺, 产 物为棕黄色固体粉末 R18。
产率: 56%; ¾-NMR (400 MHz, CDC13) δ (ppm): 11.48 (s, IH), 10.20 (s, IH), 9.04 (s, IH), 8.52 (d, J = 7.5, IH), 7.82 (d, J = 8.3, 2H), 7.73 (s, IH), 7.48 (d, J = 7.5, 2H), 7.35 - 7.29 (m, 2H), 5.30 (s, IH), 4.01 - 3.68 (m, 2H), 2.85 - 2.69 (m, 4H), 1.97 (s, 2H), 1.25 (s, 2H), 1. - 1.09 (m, 6H); ESI-MS m/z: 402[M+H] +.
化合物 R18。
以上所述的化合物 2、 3、 4、 5、 6为中间产物, 化合物 R15、 R16、 R17、 R18为目标氨基取代吴茱萸次碱类似物。
实施例 10: 应用 3T3-L1小鼠脂肪细胞模型, 采用显微镜拍照以及甘油三 酯含量测定试剂盒分析,在体外评价吴茱萸次碱 R1和式 I化合物(R17、 R18) 对减少细胞脂肪蓄积的作用。
实验步骤:
该实验设定基础对照组 BM, DMSO空白对照组 DM, 以及不同的药物组 R1 (吴茱萸次碱) 组, R17组, R18组。 具体操作如下:
将 3T3-L1前脂肪细胞接种于 48孔板。先用基础培养基培养, 直至细胞接
成分化后培养基再培育 3天(Day6)。 药物组在 DayO和 Day3时, 将相应药物 稀释于新鲜的培养基, 一同加入。 而基础对照组以及 DMSO空白对照组则加 入相应量的 DMSO。 在 Day6时用显微镜 (4倍物镜) 进行拍照以及用试剂盒 进行甘油三酯含量分析。
( 1 ) 溶液配制和药物稀释:
药物溶液: 溶于二甲亚砜(DMSO, dimethylsulfoxide) , 配成 10mM浓度, -20°C低温冰箱保存, 临用时用相应培养液稀释至所需浓度, 使 DMSO终浓度 小于或等于 0.1% (v / v
基础培养基: DMEM高糖培养基 +10%新生牛血清
分化培养基: 基础培养基中添加三联诱导剂 0.5mM异丁基-甲基-黄嘌呤, lng/ml地塞米松, 2 μ g/mL胰岛素
分化后培养基: 基础培养基中添加 2 μ g/mL胰岛素
(2) 甘油三酯含量分析
上述细胞弃去培养基, 用 PBS清洗 2次, 加入 50mM氢氧化钾溶液在 60 °C加热 lOmin, 使细胞充分裂解, 匀浆细胞悬液, 按甘油三酯测定试剂盒的使 用说明测定甘油三酯的含量。
甘油三酯含量分析的最终结果以 " 100%对照"方式表示 (即是 (药物组的 甘油三酯含量 /对照组的甘油三酯的含量) *100%)。 为了便于作浓度响应图, DMSO空白对照组的药物浓度为 Ο μ Μ设定为 0.0001 μ Μ。 实验结果为三次 独立实验的平均值。
评判标准:
药物组的甘油三酯含量, 若比 DMSO空白对照组的有所降低, 并且两组 数据在统计学上存在显著性差异, 则说明该化合物能够减少 3T3-L1脂肪细胞 的脂肪蓄积。
实验结果:
图 1中, DM是 DMSO空白对照组, 代表正常分化的细胞, 有大量的脂肪 积累; R1为吴茱萸次碱, R15-R18为氨基取代吴茱萸次碱类似物。 阳性对照 为 3 μ Μ小檗碱(BBR)。 与 DMSO空白对照组 (DM)相比, 1 μ M的化合物 Rl、 R15、 R17、 R18能够显著性地降低细胞的甘油三酯含量 (*, P<0.5; **,
/ o I , z μ /y^^ /J H /J/J t Ί/Ν μ J > ^I J¾> V jyji -Ή o 图 2显示, 吴茱萸次碱 Rl和式 I化合物 (R17 R18 ) 皆能浓度依赖性地 减少 3T3-L1细胞的脂肪蓄积 (*, P<0.5; ** P<0.1 ; *** P<0.001 ), 而 R17 和 R18的活性更强。 由图可知, 经 3 M R17和 R18处理过的细胞, 其甘油三 酯的含量分别减少了 93%和 72%。 而同一浓度下的 R1组, 其甘油三酯的含量 只减少了 34%
图 3中, BM为基础对照组, 代表未分化的细胞, 无脂肪积累。 由图片可 直观发现, 基础对照组 BM中几乎没有脂滴积累, 而 DMSO空白对照组 DM 则可以清楚地看到密集的脂滴,而药物组中的脂滴随着药物浓度的增加而逐渐 减少。
图 4中, 在 15 M Rl的图片中, 方框所示的针状物, 即为 R1因为水溶 性差而从培养基中析出来的固体。而在同一条件下, 15 4 ^1 1 17和1 18的显微 镜视野干净, 并没有固体物析出。 这说明了类似物 R17和 R18的水溶性确实 比 R1好。
实施例 11: 应用另一细胞株 FAO大鼠肝细胞作为模型, 采用甘油三酯含 量测定试剂盒以及 BCA蛋白浓度测定试剂盒分析,在体外评价吴茱萸次碱 R1 和式 I化合物 (R17) 对高果糖诱导的肝细胞脂肪蓄积减少作用。
实验步骤:
该实验设定基础对照组 Bas (不含果糖), DMSO空白对照组 Fm (含高果糖), 以及不同的药物组 R1组和 R17组。 具体操作如下:
将 FAO大鼠肝细胞以 5*105个 /孔接种于 24孔板,培养 24h, 然后换成果 糖培养基, 再培养 24h, 然后进行甘油三酯和蛋白含量测定, 结果分析。 此实 验中, 药物组是将药物用果糖培养基稀释至所需浓度, 一同加入, 孵育 24h 而基础对照组以及 DMSO空白对照组则加入相应量的 DMSO, —同孵育 24h
(1) 溶液配制和药物稀释:
药物溶液: 同试验实施例 10
果糖培养基: 低糖 DMEM培养基中添加 25mM的果糖, 再添加 10%新生 牛血清
(2) 甘油三酯含量和蛋白含量分析
上述细胞弃去培养基, 用 PBS清洗 2次, 加入 1M氢氧化钾溶液在 60°C
说明测定每孔的甘油三酯的含量, 按 BCA蛋白含量测定试剂盒的使用说明测 定每孔的蛋白含量。
最后甘油三酯水平的分析结果以 nmol/mg蛋白表示。但为了便于两个化合 物之间的对照比较, 又将此结果转换成 " 100%对照"方式表示 (即是药物组的 甘油三酯含量 (nmol/mg蛋白) /对照组的甘油三酯的含量 (nmol/mg蛋白) *100%)。为了便于作浓度响应图, DMSO空白对照组的药物浓度为 Ο μ Μ设定 为 0.0001 μ Μ。 实验结果为三次独立实验的平均值。
实验结果:
图 5显示茱萸次碱 R1和式 I化合物(R17)浓度依赖性地抑制了高果糖诱 导的 FAO大鼠肝细胞脂肪积累。 可以明显地看到, 在浓度为 ΙΟ μ Μ时, R1 组高果糖诱导的脂肪蓄积减少了 72%, 而 R17组减少了 92% (*, Ρ<0.5; **, Ρ<0.1 ; ***, Ρ<0.001
图 6 为化合物 Rl、 R17、 R18与细胞孵育 24 h后用显微镜拍照所得图片。 由图可以清晰地看到, 由于水溶性差, R1在 20 μ Μ下会从培养基中析出,而 20 μ Μ 的 R17和 R18则不会出现此现象。 图中方框所圈的针状物即为从培养 基中析出来的固体。 再次说明了类似物 R17和 R18的水溶性确实比 R1好。
Claims
1.一种氨基取代吴茱萸次碱 其特征在于化学式为
式中, R。 = -NH(CH2)„R2, 11 = 1、2、3、4或5, 1 2 = -N(CH3)2、 -N(CH2CH3)2、 环戊胺基或环己胺基; 或者 吗啉基、 哌嗪基或甲基哌嗪基。
2. 一种权利要求 1所述氨基取代吴茱萸次碱类似物的制备方法, 其特征 在于包括以下步骤:
邻氨基苯甲酰胺 1 与原丙酸三乙酯反应得到化合
、 N.
/
3. 根据权利要求 2所述的制备方法,其特征在于所述取代胺化合物为 HR。, R0 = -NH(CH2)nR2, n = l、 2、 3、 4或 5, R2 = -N(CH3)2、 -N(CH2CH3)2、 环戊
4. 根据权利要求 2所述的制备方法, 其特征在于制备化合
0
L
„上 X
在室温下与三氯氧磷反应, 经环合氯代后得到化合物 6
6. 根据权利要求 2~5中任一项所述的制备方法, 其特征在于目标产物 7 通过柱层析进行纯化。
7. 权利要求 1所述的氨基取代吴茱萸次碱类似物在制备抗肥胖症药物中 的应用。
8. 一种抗肥胖症药物,其特征在于含有权利要求 1所述氨基取代吴茱萸次 碱类似物以及药学上可接受的辅助剂。
9. 根据权利要求 8所述的抗肥胖症药物, 其特征在于所述药物为注射剂、 片剂、 丸剂、 胶囊剂、 悬浮剂或乳剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210302084.5 | 2012-08-23 | ||
CN201210302084.5A CN102775413B (zh) | 2012-08-23 | 2012-08-23 | 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014029360A1 true WO2014029360A1 (zh) | 2014-02-27 |
Family
ID=47120544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/082166 WO2014029360A1 (zh) | 2012-08-23 | 2013-08-23 | 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102775413B (zh) |
WO (1) | WO2014029360A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102775413B (zh) * | 2012-08-23 | 2014-07-16 | 中山大学 | 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 |
CN103059020A (zh) * | 2012-12-10 | 2013-04-24 | 中山大学 | 一种吴茱萸次碱衍生物及其制备方法和应用 |
CN113171366A (zh) * | 2021-03-30 | 2021-07-27 | 安徽医科大学 | 一种3-(邻三氟甲氧基苯磺酰氨)吴茱萸次碱在制备防治酒精性肝损伤药物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101005856A (zh) * | 2004-08-19 | 2007-07-25 | 皮肤应用遗传学股份有限公司 | 吴茱萸果实提取物的仿生物用于缓解炎症 |
CN101597294A (zh) * | 2009-06-05 | 2009-12-09 | 中山大学 | 3-胺基烷酰胺基-吴茱萸次碱与3-胺基烷酰胺基-7,8-脱氢吴茱萸次碱衍生物 |
CN101810715A (zh) * | 2009-02-24 | 2010-08-25 | 成都中医药大学附属医院 | 吴茱萸及其提取物、化合物的新用途 |
CN101953838A (zh) * | 2010-08-13 | 2011-01-26 | 李岱 | 吴茱萸次碱用于治疗银屑病的应用 |
CN102775413A (zh) * | 2012-08-23 | 2012-11-14 | 中山大学 | 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63287724A (ja) * | 1987-05-20 | 1988-11-24 | Tsumura & Co | 脳機能改善剤 |
WO2005123735A1 (ja) * | 2004-06-16 | 2005-12-29 | Kyowa Hakko Kogyo Co., Ltd. | エボジアミン類含有組成物の製造方法 |
-
2012
- 2012-08-23 CN CN201210302084.5A patent/CN102775413B/zh active Active
-
2013
- 2013-08-23 WO PCT/CN2013/082166 patent/WO2014029360A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101005856A (zh) * | 2004-08-19 | 2007-07-25 | 皮肤应用遗传学股份有限公司 | 吴茱萸果实提取物的仿生物用于缓解炎症 |
CN101810715A (zh) * | 2009-02-24 | 2010-08-25 | 成都中医药大学附属医院 | 吴茱萸及其提取物、化合物的新用途 |
CN101597294A (zh) * | 2009-06-05 | 2009-12-09 | 中山大学 | 3-胺基烷酰胺基-吴茱萸次碱与3-胺基烷酰胺基-7,8-脱氢吴茱萸次碱衍生物 |
CN101953838A (zh) * | 2010-08-13 | 2011-01-26 | 李岱 | 吴茱萸次碱用于治疗银屑病的应用 |
CN102775413A (zh) * | 2012-08-23 | 2012-11-14 | 中山大学 | 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102775413B (zh) | 2014-07-16 |
CN102775413A (zh) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU717913B2 (en) | Xanthines and their therapeutic use | |
EA023574B1 (ru) | ПРОИЗВОДНЫЕ 6-ЦИКЛОБУТИЛ-1,5-ДИГИДРОПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE9A | |
WO2016086824A1 (zh) | 一种Bouchardatine和Bouchardatine衍生物及其制备方法和应用 | |
KR20160048883A (ko) | 약제학적 화합물 | |
WO2017086430A1 (ja) | Nashの治療又は予防のための医薬組成物 | |
US11944616B2 (en) | Dizocilpine derivatives as peripheral NMDA receptor antagonists | |
JP2022549923A (ja) | Nヘテロ五員環含有カプシドタンパク質集合阻害剤の結晶形及びその使用 | |
Zhang et al. | Discovery of tetrahydrocarbazoles with potent hypoglycemic and hypolipemic activities | |
WO2016168349A1 (en) | Methods of treating hepatitis b virus | |
WO2014029360A1 (zh) | 氨基取代吴茱萸次碱类似物及其合成方法与在制备抗肥胖症药物中的应用 | |
CN111712491A (zh) | 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
WO2011160597A1 (zh) | 一种具有降高血压活性的呋喃香豆素类化合物及其制备方法 | |
US20220402918A1 (en) | Group of tetrahydroindoloquinazoline compounds and use thereof | |
CN111067949B (zh) | 具有抑制脂肪蓄积作用的粘委陵菜总黄酮有效部位及其制备方法和应用 | |
CN106397408B (zh) | 5-甲基-2(1h)吡啶酮衍生物及其制备方法和用途 | |
EP3974418A1 (en) | Crystal form of 1,4-[bis(1,2-benzisoselenazol-3(2h)-one)]butane, preparation method therefor, and application thereof | |
US20230045031A1 (en) | Diarylamide Compound and Application Thereof | |
CN101829086B (zh) | 芳氨甲酰脱氢水飞蓟宾作为制备治疗病毒性乙肝药物的用途 | |
CN112189009A (zh) | 作为tcr-nck相互作用的抑制剂的色烯衍生物 | |
CN111789855A (zh) | 3β-甲磺酰氧基齐墩果酸用于制备抗病毒性乙肝的医药用途 | |
CN115279761A (zh) | 咪唑并吡啶酮化合物或其盐的晶体 | |
CN111789848A (zh) | 双羟基齐墩果烷12-烯用于制备抗病毒性乙肝药物的用途 | |
CN111759846A (zh) | A环双键齐墩果酸用于制备防治病毒性乙肝的医药用途 | |
CN111870605A (zh) | 3β,28-齐墩果烷二醇用于制备抗病毒性乙肝药物的用途 | |
CN115244054A (zh) | 次黄嘌呤化合物的晶体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13830497 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13830497 Country of ref document: EP Kind code of ref document: A1 |